Edition:
India

Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

21.79USD
24 Jun 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$21.79
Open
$22.77
Day's High
$22.92
Day's Low
$21.77
Volume
207,791
Avg. Vol
263,519
52-wk High
$39.20
52-wk Low
$17.90

Latest Key Developments (Source: Significant Developments)

Editas and BlueRock Enter Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE AND BLUEROCK THERAPEUTICS ENTER STRATEGIC RESEARCH COLLABORATION AND CROSS-LICENSING AGREEMENT TO COMBINE GENOME EDITING AND CELL THERAPY PLATFORMS.EDITAS MEDICINE - EACH PARTY WILL PAY FOR CERTAIN MILESTONES TO RESPECTIVE PARTNER FOR LICENSED ENGINEERED CELL MEDICINE DEVELOPED IN RESPECTIVE FIELD.  Full Article

Editas Medicine Says Chief Medical Officer Will Step Down At End Of Year
Tuesday, 28 Aug 2018 

Aug 27 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE ANNOUNCES TRANSITION OF CHIEF MEDICAL OFFICER.EDITAS MEDICINE - CHIEF MEDICAL OFFICER, GERALD COX WILL BE STEPPING DOWN AT END OF YEAR.  Full Article

Allergan And Editas Medicine Announce To Jointly Develop Crispr Genome Editing Experimental Medicine Edit-101
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Allergan plc ::ALLERGAN AND EDITAS MEDICINE ANNOUNCE EXERCISE OF OPTIONS TO JOINTLY DEVELOP CRISPR GENOME EDITING EXPERIMENTAL MEDICINE EDIT-101.EXERCISED OPTION TO DEVELOP & COMMERCIALIZE EDIT-101 GLOBALLY FOR TREATMENT OF LCA10.HAS PAID EDITAS MEDICINE A FEE OF $15 MILLION IN CONJUNCTION WITH EXERCISE OF ITS OPTION.ADDITIONALLY, EDITAS MEDICINE HAS EXERCISED ITS OPTION TO CO-DEVELOP, SHARE EQUALLY IN PROFITS AND LOSSES FROM EDIT-101 IN U.S..EDITAS MEDICINE ELIGIBLE TO RECEIVE ADDITIONAL $25 MILLION FROM ALLERGAN UPON ACCEPTANCE OF IND APPLICATION FOR EDIT-101 BY FDA.  Full Article

Editas Medicine Reports Data Demonstrating Subretinal Injection Of Edit-101 Well-Tolerated In Non-Human Primates
Saturday, 19 May 2018 

Editas Medicine Inc ::EDITAS MEDICINE REPORTS DATA DEMONSTRATING SUBRETINAL INJECTION OF EDIT-101 WELL-TOLERATED IN NON-HUMAN PRIMATES.EDITAS MEDICINE INC - BOTH EDIT-101 AND VIR-067 WERE WELL TOLERATED IN ANIMALS TREATED WITH PROPHYLACTIC STEROIDS.EDITAS MEDICINE INC - EDITAS MEDICINE AIMS TO FILE AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR EDIT-101 BY MID-2018.  Full Article

Editas Medicine Reports Q1 Loss Per Share Of $0.67
Friday, 4 May 2018 

May 3 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE ANNOUNCES FIRST QUARTER 2018 RESULTS AND UPDATE.Q1 LOSS PER SHARE $0.67.Q1 REVENUE $3.9 MILLION VERSUS I/B/E/S VIEW $4 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.82 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $359 MILLION AS OF MARCH 31, 2018.  Full Article

Editas Medicine Files For Potential Stock Shelf, Size Undisclosed - SEC Filing
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE INC FILES FOR POTENTIAL STOCK SHELF, SIZE UNDISCLOSED - SEC FILING.  Full Article

Editas Medicine Announces Pricing Of $50 Mln Offering Of Common Stock
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE, INC., ANNOUNCES PRICING OF $50 MILLION OFFERING OF COMMON STOCK.EDITAS MEDICINE INC - ‍PRICING OF AN UNDERWRITTEN OFFERING OF 1.97 MILLION SHARES OF ITS COMMON STOCK​.  Full Article

Editas Medicine Announces Offering Of Common Stock
Wednesday, 6 Dec 2017 

Dec 5 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE, INC., ANNOUNCES OFFERING OF COMMON STOCK.EDITAS MEDICINE INC - INTENDS TO OFFER AND SELL $50 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Editas Medicine announces Q3 loss per share $0.64
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Editas Medicine Inc ::Editas Medicine announces third quarter 2017 results and update.Q3 loss per share $0.64.Q3 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S.Editas Medicine Inc - ‍cash, cash equivalents, and marketable securities at Sept. 30, 2017, were $295.7 million, compared to $199.9 million at Sept. 30, 2016​.  Full Article